Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-JIA: Sequential Medications After TNFi Failure in JIA
NCT06654882Phase 3Recruiting
- Sponsor
- Duke University
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 3 trial of abatacept, tocilizumab, tofacitinib oral solution in juvenile idiopathic arthritis (JIA), sponsored by Duke University. Started Jan 2026; status: recruiting.
02
Drugs
abatacepttocilizumabtofacitinib oral solution
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT06654882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654882.